title: Why We Should Be Willing to Pay for Hepatitis C Treatment.
authors.affiliation: Institute for Technology Assessment, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
authors.forename: Jagpreet
authors.initials: J
authors.lastname: Chhatwal
authors.affiliation: H. Milton Stewart School of Industrial and Systems Engineering, Georgia Institute of Technology, Atlanta, Georgia.
authors.forename: Qiushi
authors.initials: Q
authors.lastname: Chen
authors.affiliation: Houston Veterans Affairs Health Services Research and Development Center of Excellence, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas; Department of Medicine, Gastroenterology and Hepatology, Baylor College of Medicine, Houston, Texas.
authors.forename: Fasiha
authors.initials: F
authors.lastname: Kanwal
mesh_terms: D000998:Antiviral Agents / Q000191:economics* / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D017048:Health Care Costs; D006297:Health Services Accessibility; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000453:epidemiology* / Q000635:transmission; D006801:Humans
chemical_list: D000998:Antiviral Agents